

EXPRESS NIL NO.: EL897863581US



PTO/SB/01A (10-00).

Approved for the through 10/31/2002. SMB 0651-0032. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE. Under the Paperwork Reduction act of 1995, no people is are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	AMINOALKYL GLUCOSAMINIDE THEIR USE AS ADJUVANTS AND			
As the below named in	ventor(s), I/we declare that:			
This declaration is directed to:				
The attached application, or				
Application No. <u>10/043,086</u> , filed on <u>January 8, 2002</u> ,				
as amended on (if applicable);				
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;				
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;				
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable; and				
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
FULL NAME OF INVENTOR(S)				
Inventor one: Davi	d A. Johnson	Citizen of:	U.S.	
Signature:	mid be from	Date:	02/15/02	
Inventor two: C. G	regory Sowell	Citizen of:	U.S.	
Signature:		Date:		
Inventor three:		Citizen of:		
Signature:		Date:		
Inventor four:		Citizen of:		
Signature:		Date:		
Additional inventors are being named onadditional form(s) attached bereto				

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Docket No. 210121.489C2

EXPRESS MAIL NO.: EL897863581US


PTO/SB/01A (10-00). Approved for use through 1004 2002. OMB 085 20032. U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE. Under the Paperwork Reduction Act of 1995. Page required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS			
As the below named inventor(s), I/we declare that:				
This declaration is directed to:				
The attached application, or				
Application No. <u>10/043,086</u> , filed on <u>January 8, 2002</u> ,				
as amended on (if applicable);				
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;				
I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;				
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including material information which became available between the filing date of the prior application and the National or PCT International filing date of the continuation-in-part application, if applicable; and				
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
FULL NAME OF INVENTOR(S)				
Inventor one: David	A. Johnson	Citizen of:	U.S.	
Signature:		Date:		
Inventor two: C. Gr	egory Sowell	Citizen of:	U.S.	
Signature:	By LowM	Date:	2/21/02	
Inventor three:		Citizen of:		
Signature:		Date:		
Inventor four:		Citizen of:		
Signature:		Date:		
Additional inventors are being named on additional form(s) attached hereto.				

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Docket No. 210121.489C2



EXPRESS MAIL NO. EL897863581U
PTO/SB/96 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1998 are required to respond to a collection of information unless it displays a valid OMB control number.

<u>STATEMI</u>	ENT UNDER 37 CFR 3.73(b)				
Applicant/Patent Owner:David A.	Johnson				
Application No./Patent No.: 10/043,08	6 Filed/Issue Date: January 8, 2002				
Entitled: AMINOALKYL GLUCOSAMIN ADJUVANTS AND IMMUNOE	FFECTORS				
Corixa Corporation	, a <u>corporation</u>				
(Name of Assignee)	(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)				
states that it is:					
1. X the assignee of the entire right, tit	le, and interest; or				
2. an assignee of an undivided part	interest				
in the patent application/patent identified	d above by virtue of either:				
The assignment was recorded in	s) of the patent application/patent identified above. the United States Patent and Trademark Office at which a copy thereof is attached.				
B. A chain of title from the inventor(s current assignee as shown below	s), of the patent application/patent identified above, to the				
1. From:	To:				
	the United States Patent and Trademark Office at or which a copy thereof is attached				
2. From:	To:				
	the United States Patent and Trademark Office at or which a copy thereof is attached				
3. From:	To:				
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.					
Additional documents in the chain of title are listed on a supplemental sheet.					
Copies of assignments or other docu	uments in the chain of title are attached.				
[NOTE: A separate copy (i.e., the original as:	signment document or a true copy of the original document) must be nce with 37 CFR Part 3, if the assignment is to be recorded in the records				
The undersigned (whose title is supplied	d below) is authorized to act on behalf of the assignee.				
22 Feb 2002	Kathleen Nora McKereghan				
Date	Typed or printed name				
	Calle M. M. Called Signature				
	Senior Vice President, General Counsel and Secretary				
	Title				

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.